|
1
|
Wu D, Huang P, Wang L, Zhou Y, Pan H and
Qu P: MicroRNA-143 inhibits cell migration and invasion by
targeting matrix metalloproteinase 13 in prostate cancer. Mol Med
Rep. 8:626–630. 2013.PubMed/NCBI
|
|
2
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mangoni M, Desideri I, Detti B, Bonomo P,
Greto D, Paiar F, Simontacchi G, Meattini I, Scoccianti S, Masoni
T, et al: Hypofractionation in prostate cancer: Radiobiological
basis and clinical appliance. Biomed Res Int. 2014:7813402014.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lafeuille MH, Gravel J, Grittner A,
Lefebvre P, Ellis L and McKenzie RS: Real-World corticosteroid
utilization patterns in patients with metastatic
castration-resistant prostate cancer in 2 large US administrative
claims databases. Am Health Drug Benefits. 6:307–316. 2013.
|
|
5
|
Nelson CJ, Lee JS, Gamboa MC and Roth AJ:
Cognitive effects of hormone therapy in men with prostate cancer: A
review. Cancer. 113:1097–1106. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Discacciati A and Wolk A: Lifestyle and
dietary factors in prostate cancer prevention. Recent Results
Cancer Res. 202:27–37. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lai GY, Giovannucci EL, Pollak MN, Peskoe
SB, Stampfer MJ, Willett WC and Platz EA: Association of C-peptide
and leptin with prostate cancer incidence in the health
professionals follow-up study. Cancer Causes Control. 25:625–632.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wu J and Yu E: Insulin-like growth factor
receptor-1 (IGF-IR) as a target for prostate cancer therapy. Cancer
Metastasis Rev. 33:607–617. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Barba M, McCann SE, Schünemann HJ,
Stranges S, Fuhrman B, De Placido S, Carruba G, Freudenheim JL,
Trevisan M, Russell M, et al: Lifetime total and beverage
specific-alcohol intake and prostate cancer risk: A case-control
study. Nutr J. 3:232004. View Article : Google Scholar
|
|
10
|
Joung JG, Kim D, Lee SY, Kang HJ and Kim
JH: Integrated analysis of microRNA-target interactions with
clinical outcomes for cancers. BMC Med Genomics. 7(Suppl 1):
S102014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Garzon R, Pichiorri F, Palumbo T,
Visentini M, Aqeilan R, Cimmino A, Wang H, Sun H, Volinia S, Alder
H, et al: MicroRNA gene expression during retinoic acid-induced
differentiation of human acute promyelocytic leukemia. Oncogene.
26:4148–4157. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Carthew RW and Sontheimer EJ: Origins and
Mechanisms of miRNAs and siRNAs. Cell. 136:642–655. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Friedman RC, Farh KK, Burge CB and Bartel
DP: Most mammalian mRNAs are conserved targets of microRNAs. Genome
Res. 19:92–105. 2009. View Article : Google Scholar :
|
|
14
|
Kwak PB, Iwasaki S and Tomari Y: The
microRNA pathway and cancer. Cancer Sci. 101:2309–2315. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Oom AL, Humphries BA and Yang C:
MicroRNAs: Novel players in cancer diagnosis and therapies. Biomed
Res Int. 2014:9594612014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Esquela-Kerscher A and Slack FJ:
Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer.
6:259–269. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang L, Li B, Li L and Wang T:
MicroRNA-497 suppresses proliferation and induces apoptosis in
prostate cancer cells. Asian Pac J Cancer Prev. 14:3499–3502. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Amate P, Huchon C, Dessapt AL, Bensaid C,
Medioni J, Le Frère Belda MA, Bats AS and Lécuru FR: Ovarian
cancer: SItes of recurrence. Int J Gynecol Cancer. 23:1590–1596.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Martignani E, Miretti S, Accornero P and
Baratta M: MiRNAs highlights in stem and cancer cells. Mini Rev Med
Chem. 11:1165–1182. 2011. View Article : Google Scholar
|
|
21
|
Hummel R, Hussey DJ and Haier J:
MicroRNAs: Predictors and modifiers of chemo- and radiotherapy in
different tumour types. Eur J Cancer. 46:298–311. 2010. View Article : Google Scholar
|
|
22
|
Finnerty JR, Wang WX, Hébert SS, Wilfred
BR, Mao G and Nelson PT: The miR-15/107 group of microRNA genes:
Evolutionary biology, cellular functions and roles in human
diseases. J Mol Biol. 402:491–509. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li D, Zhao Y, Liu C, Chen X, Qi Y, Jiang
Y, Zou C, Zhang X, Liu S, Wang X, et al: Analysis of MiR-195 and
MiR-497 expression, regulation and role in breast cancer. Clin
Cancer Res. 17:1722–1730. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xie Y, Wei RR, Huang GL, Zhang MY, Yuan YF
and Wang HY: Checkpoint kinase 1 is negatively regulated by miR-497
in hepa-tocellular carcinoma. Med Oncol. 31:8442014. View Article : Google Scholar
|
|
25
|
Guo J, Miao Y, Xiao B, Huan R, Jiang Z,
Meng D and Wang Y: Differential expression of microRNA species in
human gastric cancer versus non-tumorous tissues. J Gastroenterol
Hepatol. 24:652–657. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen HC, Chen GH, Chen YH, Liao WL, Liu
CY, Chang KP, Chang YS and Chen SJ: MicroRNA deregulation and
pathway alterations in nasopharyngeal carcinoma. Br J Cancer.
100:1002–1011. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hiroki E, Akahira J, Suzuki F, Nagase S,
Ito K, Suzuki T, Sasano H and Yaegashi N: Changes in microRNA
expression levels correlate with clinicopathological features and
prognoses in endometrial serous adenocarcinomas. Cancer Sci.
101:241–249. 2010. View Article : Google Scholar
|
|
28
|
Guo ST, Jiang CC, Wang GP, Li YP, Wang CY,
Guo XY, Yang RH, Feng Y, Wang FH, Tseng HY, et al: MicroRNA-497
targets insulin-like growth factor 1 receptor and has a tumour
suppressive role in human colorectal cancer. Oncogene.
32:1910–1920. 2013. View Article : Google Scholar :
|
|
29
|
Shen L, Li J, Xu L, Ma J, Li H, Xiao X,
Zhao J and Fang L: MiR-497 induces apoptosis of breast cancer cells
by targeting Bcl-w. Exp Ther Med. 3:475–480. 2012.PubMed/NCBI
|
|
30
|
Zheng D, Radziszewska A and Woo P:
MicroRNA 497 modulates interleukin 1 signalling via the MAPK/ERK
pathway. FEBS Lett. 586:4165–4172. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Luo M, Shen D, Zhou X, Chen X and Wang W:
MicroRNA-497 is a potential prognostic marker in human cervical
cancer and functions as a tumor suppressor by targeting the
insulin-like growth factor 1 receptor. Surgery. 153:836–847. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chen X, Yun J, Fei F, Yi J, Tian R, Li S
and Gan X: Prognostic value of nuclear hepatoma-derived growth
factor (HDGF) localization in patients with breast cancer. Pathol
Res Pract. 208:437–443. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lin YW, Li CF, Chen HY, Yen CY, Lin LC,
Huang CC, Huang HY, Wu PC, Chen CH, Chen SC and Tai MH: The
expression and prognostic significance of hepatoma-derived growth
factor in oral cancer. Oral Oncol. 48:629–635. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Abouzied MM, Baader SL, Dietz F, Kappler
J, Gieselmann V and Franken S: Expression patterns and different
subcellular localization of the growth factors HDGF
(hepatoma-derived growth factor) and HRP-3 (HDGF-related protein-3)
suggest functions in addition to their mitogenic activity. Biochem
J. 378:169–176. 2004. View Article : Google Scholar
|
|
35
|
Sedlmaier A, Wernert N, Gallitzendörfer R,
Abouzied MM, Gieselmann V and Franken S: Overexpression of
hepatoma-derived growth factor in melanocytes does not lead to
oncogenic transformation. BMC Cancer. 11:4572011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ren H, Tang X, Lee JJ, Feng L, Everett AD,
Hong WK, Khuri FR and Mao L: Expression of hepatoma-derived growth
factor is a strong prognostic predictor for patients with
early-stage non-small-cell lung cancer. J Clin Oncol. 22:3230–3237.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hu TH, Huang CC, Liu LF, Lin PR, Liu SY,
Chang HW, Changchien CS, Lee CM, Chuang JH and Tai MH: Expression
of hepatoma-derived growth factor in hepatocellular carcinoma.
Cancer. 98:1444–1456. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lepourcelet M, Tou L, Cai L, Sawada J,
Lazar AJ, Glickman JN, Williamson JA, Everett AD, Redston M, Fox
EA, et al: Insights into developmental mechanisms and cancers in
the mammalian intestine derived from serial analysis of gene
expression and study of the hepatoma-derived growth factor (HDGF).
Development. 132:415–427. 2005. View Article : Google Scholar
|
|
39
|
Yamamoto S, Makuuchi H, Shimada H, Chino
O, Nishi T, Kise Y, Kenmochi T and Hara T: Clinical analysis of
reflux esophagitis following esophagectomy with gastric tube
reconstruction. J Gastroenterol. 42:342–345. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Uyama H, Tomita Y, Nakamura H, Nakamori S,
Zhang B, Hoshida Y, Enomoto H, Okuda Y, Sakon M, Aozasa K, et al:
Hepatoma-derived growth factor is a novel prognostic factor for
patients with pancreatic cancer. Clin Cancer Res. 12:6043–6048.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Bernard K, Litman E, Fitzpatrick JL,
Shellman YG, Argast G, Polvinen K, Everett AD, Fukasawa K, Norris
DA, Ahn NG and Resing KA: Functional proteomic analysis of melanoma
progression. Cancer Res. 63:6716–6725. 2003.PubMed/NCBI
|
|
42
|
Okuda Y, Nakamura H, Yoshida K, Enomoto H,
Uyama H, Hirotani T, Funamoto M, Ito H, Everett AD and Hada T:
Hepatoma-derived growth factor induces tumorigenesis in vivo
through both direct angiogenic activity and induction of vascular
endothelial growth factor. Cancer Sci. 94:1034–1041. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Matsuyama A, Inoue H, Shibuta K, Tanaka Y,
Barnard GF, Sugimachi K and Mori M: Hepatoma-derived growth factor
is associated with reduced sensitivity to irradiation in esophageal
cancer. Cancer Res. 61:5714–5717. 2001.PubMed/NCBI
|
|
44
|
Everett AD: Identification, cloning and
developmental expression of hepatoma-derived growth factor in the
developing rat heart. Dev Dyn. 222:450–458. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Everett AD, Lobe DR, Matsumura ME,
Nakamura H and McNamara CA: Hepatoma-derived growth factor
stimulates smooth muscle cell growth and is expressed in vascular
development. J Clin Invest. 105:567–575. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Oliver JA and Al-Awqati Q: An endothelial
growth factor involved in rat renal development. J Clin Invest.
102:1208–1219. 1998. View
Article : Google Scholar : PubMed/NCBI
|
|
47
|
Crossin KL, Tai MH, Krushel LA, Mauro VP
and Edelman GM: Glucocorticoid receptor pathways are involved in
the inhibition of astrocyte proliferation. Proc Natl Acad Sci USA.
94:2687–2692. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Guo Z, He Y, Wang S, Zhang A, Zhao P, Gao
C and Cao B: Various effects of hepatoma-derived growth factor on
cell growth, migration and invasion of breast cancer and prostate
cancer cells. Oncol Rep. 26:511–517. 2011.PubMed/NCBI
|
